Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

Maciej Juryńczyk, Brian G Weinshenker, Gulsen Akman-Demir, Nasrin Asgari, David Barnes, Mike Boggild, Abhijit Chaudhuri, Marie D’hooghe, Nikos Evangelou, Ruth Geraldes, Zsolt Illes, Anu Jacob, Ho Jin Kim, Ingo Kleiter, Michael Levy, Romain Marignier, Christopher McGuigan, Katy Murray, Ichiro Nakashima, Lekha Pandit & 11 others Friedemann Paul, Sean J Pittock, Krzysztof Selmaj, Jérôme de Sèze, Aksel Siva, Radu Tanasescu, Sandra Vukusic, Dean Marko Wingerchuk, Damian Wren, Isabel Leite, Jacqueline Palace

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Distinguishing aquaporin-4 IgG(AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD) from opticospinal predominant multiple sclerosis (MS) is a clinical challenge with important treatment implications. The objective of the study was to examine whether expert clinicians diagnose and treat NMO/MS overlapping patients in a similar way. 12 AQP4-IgG-negative patients were selected to cover the range of clinical scenarios encountered in an NMO clinic. 27 NMO and MS experts reviewed their clinical vignettes, including relevant imaging and laboratory tests. Diagnoses were categorized into four groups (NMO, MS, indeterminate, other) and management into three groups (MS drugs, immunosuppression, no treatment). The mean proportion of agreement for the diagnosis was low (po = 0.51) and ranged from 0.25 to 0.73 for individual patients. The majority opinion was divided between NMOSD versus: MS (nine cases), monophasic longitudinally extensive transverse myelitis (LETM) (1), acute disseminated encephalomyelitis (ADEM) (1) and recurrent isolated optic neuritis (RION) (1). Typical NMO features (e.g., LETM) influenced the diagnosis more than features more consistent with MS (e.g., short TM). Agreement on the treatment of patients was higher (po = 0.64) than that on the diagnosis with immunosuppression being the most common choice not only in patients with the diagnosis of NMO (98 %) but also in those indeterminate between NMO and MS (74 %). The diagnosis in AQP4-IgG-negative NMO/MS overlap syndromes is challenging and diverse. The classification of such patients currently requires new diagnostic categories, which incorporate lesser degrees of diagnostic confidence. Long-term follow-up may identify early features or biomarkers, which can more accurately distinguish the underlying disorder.

Original languageEnglish (US)
Pages (from-to)140-149
Number of pages10
JournalJournal of Neurology
Volume263
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Multiple Sclerosis
Immunoglobulin G
Transverse Myelitis
Neuromyelitis Optica
Immunosuppression
Acute Disseminated Encephalomyelitis
Aquaporin 4
Optic Neuritis
Therapeutics
Biomarkers
Pharmaceutical Preparations

Keywords

  • All demyelinating disease (CNS)
  • Devic’s syndrome
  • Multiple sclerosis
  • Optic neuritis
  • Transverse myelitis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Juryńczyk, M., Weinshenker, B. G., Akman-Demir, G., Asgari, N., Barnes, D., Boggild, M., ... Palace, J. (2016). Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 263(1), 140-149. https://doi.org/10.1007/s00415-015-7952-8

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. / Juryńczyk, Maciej; Weinshenker, Brian G; Akman-Demir, Gulsen; Asgari, Nasrin; Barnes, David; Boggild, Mike; Chaudhuri, Abhijit; D’hooghe, Marie; Evangelou, Nikos; Geraldes, Ruth; Illes, Zsolt; Jacob, Anu; Kim, Ho Jin; Kleiter, Ingo; Levy, Michael; Marignier, Romain; McGuigan, Christopher; Murray, Katy; Nakashima, Ichiro; Pandit, Lekha; Paul, Friedemann; Pittock, Sean J; Selmaj, Krzysztof; de Sèze, Jérôme; Siva, Aksel; Tanasescu, Radu; Vukusic, Sandra; Wingerchuk, Dean Marko; Wren, Damian; Leite, Isabel; Palace, Jacqueline.

In: Journal of Neurology, Vol. 263, No. 1, 01.01.2016, p. 140-149.

Research output: Contribution to journalArticle

Juryńczyk, M, Weinshenker, BG, Akman-Demir, G, Asgari, N, Barnes, D, Boggild, M, Chaudhuri, A, D’hooghe, M, Evangelou, N, Geraldes, R, Illes, Z, Jacob, A, Kim, HJ, Kleiter, I, Levy, M, Marignier, R, McGuigan, C, Murray, K, Nakashima, I, Pandit, L, Paul, F, Pittock, SJ, Selmaj, K, de Sèze, J, Siva, A, Tanasescu, R, Vukusic, S, Wingerchuk, DM, Wren, D, Leite, I & Palace, J 2016, 'Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes', Journal of Neurology, vol. 263, no. 1, pp. 140-149. https://doi.org/10.1007/s00415-015-7952-8
Juryńczyk, Maciej ; Weinshenker, Brian G ; Akman-Demir, Gulsen ; Asgari, Nasrin ; Barnes, David ; Boggild, Mike ; Chaudhuri, Abhijit ; D’hooghe, Marie ; Evangelou, Nikos ; Geraldes, Ruth ; Illes, Zsolt ; Jacob, Anu ; Kim, Ho Jin ; Kleiter, Ingo ; Levy, Michael ; Marignier, Romain ; McGuigan, Christopher ; Murray, Katy ; Nakashima, Ichiro ; Pandit, Lekha ; Paul, Friedemann ; Pittock, Sean J ; Selmaj, Krzysztof ; de Sèze, Jérôme ; Siva, Aksel ; Tanasescu, Radu ; Vukusic, Sandra ; Wingerchuk, Dean Marko ; Wren, Damian ; Leite, Isabel ; Palace, Jacqueline. / Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. In: Journal of Neurology. 2016 ; Vol. 263, No. 1. pp. 140-149.
@article{f25e0cdbf25148b4b1a948a8fde2a3e5,
title = "Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes",
abstract = "Distinguishing aquaporin-4 IgG(AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD) from opticospinal predominant multiple sclerosis (MS) is a clinical challenge with important treatment implications. The objective of the study was to examine whether expert clinicians diagnose and treat NMO/MS overlapping patients in a similar way. 12 AQP4-IgG-negative patients were selected to cover the range of clinical scenarios encountered in an NMO clinic. 27 NMO and MS experts reviewed their clinical vignettes, including relevant imaging and laboratory tests. Diagnoses were categorized into four groups (NMO, MS, indeterminate, other) and management into three groups (MS drugs, immunosuppression, no treatment). The mean proportion of agreement for the diagnosis was low (po = 0.51) and ranged from 0.25 to 0.73 for individual patients. The majority opinion was divided between NMOSD versus: MS (nine cases), monophasic longitudinally extensive transverse myelitis (LETM) (1), acute disseminated encephalomyelitis (ADEM) (1) and recurrent isolated optic neuritis (RION) (1). Typical NMO features (e.g., LETM) influenced the diagnosis more than features more consistent with MS (e.g., short TM). Agreement on the treatment of patients was higher (po = 0.64) than that on the diagnosis with immunosuppression being the most common choice not only in patients with the diagnosis of NMO (98 {\%}) but also in those indeterminate between NMO and MS (74 {\%}). The diagnosis in AQP4-IgG-negative NMO/MS overlap syndromes is challenging and diverse. The classification of such patients currently requires new diagnostic categories, which incorporate lesser degrees of diagnostic confidence. Long-term follow-up may identify early features or biomarkers, which can more accurately distinguish the underlying disorder.",
keywords = "All demyelinating disease (CNS), Devic’s syndrome, Multiple sclerosis, Optic neuritis, Transverse myelitis",
author = "Maciej Juryńczyk and Weinshenker, {Brian G} and Gulsen Akman-Demir and Nasrin Asgari and David Barnes and Mike Boggild and Abhijit Chaudhuri and Marie D’hooghe and Nikos Evangelou and Ruth Geraldes and Zsolt Illes and Anu Jacob and Kim, {Ho Jin} and Ingo Kleiter and Michael Levy and Romain Marignier and Christopher McGuigan and Katy Murray and Ichiro Nakashima and Lekha Pandit and Friedemann Paul and Pittock, {Sean J} and Krzysztof Selmaj and {de S{\`e}ze}, J{\'e}r{\^o}me and Aksel Siva and Radu Tanasescu and Sandra Vukusic and Wingerchuk, {Dean Marko} and Damian Wren and Isabel Leite and Jacqueline Palace",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s00415-015-7952-8",
language = "English (US)",
volume = "263",
pages = "140--149",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

TY - JOUR

T1 - Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes

AU - Juryńczyk, Maciej

AU - Weinshenker, Brian G

AU - Akman-Demir, Gulsen

AU - Asgari, Nasrin

AU - Barnes, David

AU - Boggild, Mike

AU - Chaudhuri, Abhijit

AU - D’hooghe, Marie

AU - Evangelou, Nikos

AU - Geraldes, Ruth

AU - Illes, Zsolt

AU - Jacob, Anu

AU - Kim, Ho Jin

AU - Kleiter, Ingo

AU - Levy, Michael

AU - Marignier, Romain

AU - McGuigan, Christopher

AU - Murray, Katy

AU - Nakashima, Ichiro

AU - Pandit, Lekha

AU - Paul, Friedemann

AU - Pittock, Sean J

AU - Selmaj, Krzysztof

AU - de Sèze, Jérôme

AU - Siva, Aksel

AU - Tanasescu, Radu

AU - Vukusic, Sandra

AU - Wingerchuk, Dean Marko

AU - Wren, Damian

AU - Leite, Isabel

AU - Palace, Jacqueline

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Distinguishing aquaporin-4 IgG(AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD) from opticospinal predominant multiple sclerosis (MS) is a clinical challenge with important treatment implications. The objective of the study was to examine whether expert clinicians diagnose and treat NMO/MS overlapping patients in a similar way. 12 AQP4-IgG-negative patients were selected to cover the range of clinical scenarios encountered in an NMO clinic. 27 NMO and MS experts reviewed their clinical vignettes, including relevant imaging and laboratory tests. Diagnoses were categorized into four groups (NMO, MS, indeterminate, other) and management into three groups (MS drugs, immunosuppression, no treatment). The mean proportion of agreement for the diagnosis was low (po = 0.51) and ranged from 0.25 to 0.73 for individual patients. The majority opinion was divided between NMOSD versus: MS (nine cases), monophasic longitudinally extensive transverse myelitis (LETM) (1), acute disseminated encephalomyelitis (ADEM) (1) and recurrent isolated optic neuritis (RION) (1). Typical NMO features (e.g., LETM) influenced the diagnosis more than features more consistent with MS (e.g., short TM). Agreement on the treatment of patients was higher (po = 0.64) than that on the diagnosis with immunosuppression being the most common choice not only in patients with the diagnosis of NMO (98 %) but also in those indeterminate between NMO and MS (74 %). The diagnosis in AQP4-IgG-negative NMO/MS overlap syndromes is challenging and diverse. The classification of such patients currently requires new diagnostic categories, which incorporate lesser degrees of diagnostic confidence. Long-term follow-up may identify early features or biomarkers, which can more accurately distinguish the underlying disorder.

AB - Distinguishing aquaporin-4 IgG(AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD) from opticospinal predominant multiple sclerosis (MS) is a clinical challenge with important treatment implications. The objective of the study was to examine whether expert clinicians diagnose and treat NMO/MS overlapping patients in a similar way. 12 AQP4-IgG-negative patients were selected to cover the range of clinical scenarios encountered in an NMO clinic. 27 NMO and MS experts reviewed their clinical vignettes, including relevant imaging and laboratory tests. Diagnoses were categorized into four groups (NMO, MS, indeterminate, other) and management into three groups (MS drugs, immunosuppression, no treatment). The mean proportion of agreement for the diagnosis was low (po = 0.51) and ranged from 0.25 to 0.73 for individual patients. The majority opinion was divided between NMOSD versus: MS (nine cases), monophasic longitudinally extensive transverse myelitis (LETM) (1), acute disseminated encephalomyelitis (ADEM) (1) and recurrent isolated optic neuritis (RION) (1). Typical NMO features (e.g., LETM) influenced the diagnosis more than features more consistent with MS (e.g., short TM). Agreement on the treatment of patients was higher (po = 0.64) than that on the diagnosis with immunosuppression being the most common choice not only in patients with the diagnosis of NMO (98 %) but also in those indeterminate between NMO and MS (74 %). The diagnosis in AQP4-IgG-negative NMO/MS overlap syndromes is challenging and diverse. The classification of such patients currently requires new diagnostic categories, which incorporate lesser degrees of diagnostic confidence. Long-term follow-up may identify early features or biomarkers, which can more accurately distinguish the underlying disorder.

KW - All demyelinating disease (CNS)

KW - Devic’s syndrome

KW - Multiple sclerosis

KW - Optic neuritis

KW - Transverse myelitis

UR - http://www.scopus.com/inward/record.url?scp=84955687637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955687637&partnerID=8YFLogxK

U2 - 10.1007/s00415-015-7952-8

DO - 10.1007/s00415-015-7952-8

M3 - Article

VL - 263

SP - 140

EP - 149

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 1

ER -